Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine November 2017, 58 (11) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

PSMA α-therapy: Fendler and Cutler look at the history of α-emitter therapy and discuss the clinical benefits of such therapy directed at the prostate-specific membrane antigen.

Page 1709

Clinical utility of amyloid imaging: Barthel and Sabri review current applications of amyloid imaging, its effects on diagnosis and patient management, and remaining questions to be answered about relevance to patient outcomes.

Page 1711

Current concepts in 68Ga-DOTATATE PET/CT: Bodei and colleagues provide an educational overview of the performance and interpretation of PET/CT imaging with this somatostatin analog and of its role in the diagnosis and management of neuroendocrine neoplasms.

Page 1718

Metabolic imaging of infection: Lawal and colleagues describe metabolic and molecular techniques currently available for clinical use in infection imaging and those that have demonstrated promising results in preclinical studies with potential for clinical applications.

Page 1727

U.S. nuclear medicine training: Segall and representatives of the American Board of Nuclear Medicine review the board’s collaborative efforts to define dual training and other educational pathways in nuclear medicine and comment on an article on this topic in the October issue of JNM.

Page 1733

Curative theranostic pretargeting of CRC: Cheal and colleagues test the hypothesis that a fractionated anti–glycoprotein A33 DOTA pretargeted radioimmunotherapy regimen will lead to well-tolerated tumor cures in nude mice bearing subcutaneous GPA33-positive xenografts.

Page 1735

In vivo quantification of ERβ: Antunes and colleagues report on 18F-FHNP PET studies designed to investigate several pharmacokinetic analysis methods to quantify changes in estrogen receptor–β availability in tumor-bearing rats.

Page 1743

Succinate and 18F-FDG: Garrigue and colleagues elucidate associations among accumulation of succinate from tricarboxylic acid cycle defects, succinate dehydrogenase–mutated tumors, and 18F-FDG uptake profiles in pheochromocytomas and paragangliomas.

Page 1749

PET and esophageal adenocarcinoma: Xi and colleagues explore the question of whether 18F-FDG PET response after induction chemotherapy and before concurrent chemoradiotherapy can identify patients with esophageal adenocarcinoma who may benefit from subsequent esophagectomy.

Page 1756

PET and circulating tumor DNA: Morbelli and colleagues investigate the relationships between circulating tumor cells or plasma cell–free DNA and a comprehensive range of 18F-FDG PET/CT–derived parameters in chemotherapy-naive patients with advanced non–small cell lung cancer.

Page 1764

Test–retest variability in SUR: Hofheinz and colleagues determine whether the tumor-to-blood SUV ratio can improve test–retest variability in tracer uptake in quantitative assessment of radio- and chemotherapy response with 18F-FDG whole-body PET.

Page 1770

Detection of bone metastases: Ulaner offers perspective on newer and older imaging modalities for detection of bone metastases and previews an article on this topic in this issue of JNM.

Page 1776

Comparing diagnostic approaches in bone mets: Löfgren and colleagues prospectively evaluate and compare the diagnostic performances of 99mTc-HDP planar bone scintigraphy, 99mTc-HDP SPECT/CT, 18F-NaF PET/CT, and 18F-NaF PET/MR imaging for detection of bone metastases.

Page 1778

177Lu-PSMA-617 syngeneic model: Fendler and colleagues optimize specific and total activity levels for 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer and discuss potential advantages in studies of pharmacologic agents.

Page 1786

68Ga-DOTATATE PET/CT and management: Calais and colleagues investigate the documented clinical effect of 68Ga-DOTATATE PET/CT on the management of patients with neuroendocrine tumors, using data from a prospective referring physician–based survey.

Page 1793

Dual-timepoint 18F-DCFPyL PET/CT: Wondergem and colleagues report on the effects of PET/CT imaging at 120 and 60 min after injection of this prostate-specific membrane antigen tracer in patients with histopathologically proven prostate cancer.

Page 1797

18F-PSMA-1007 PET/CT for local staging: Kesch and colleagues examine the value of the new PET tracer 18F-PSMA-1007 for staging of local disease in prostate cancer and compare results with those from multiparametric MR imaging and radical prostatectomy histopathology.

Page 1805

18F-fluoride PET aortic valve imaging: Doris and colleagues investigate whether motion correction of gated 18F-fluoride PET/CT and PET/MR images of the aortic valve can improve PET quantitation and image quality.

Page 1811

VMAT2 imaging in CUPS: Alexander and colleagues assess the management effect of vesicular monoamine transporter type 2 imaging with 18F-AV-133 PET in patients with clinically uncertain Parkinsonian syndromes.

Page 1815

123I-ioflupane SPECT interpretation: Booij and colleagues research the effect of the addition of image quantification to 123I-ioflupane SPECT compared with visual interpretation alone in differentiating Parkinson syndrome from essential tremor and dementia with Lewy bodies from Alzheimer disease.

Page 1821

Antibiotics and 18F-FDG uptake: Kagna and colleagues determine whether antibiotic therapy affects the detectability rate for infectious processes by 18F-FDG PET/CT.

Page 1827

CXCR4-targeted renal imaging: Derlin and colleagues integrate MR imaging and chemokine receptor CXCR4-targeted PET for detection of leukocyte infiltration in patients with complicated urinary tract infections after kidney transplantation.

Page 1831

PET of EphA2 ADCs: Jacobson and colleagues use PET imaging to study the pharmacokinetics and tumor delivery of a panel of anti–erythropoietin-producing hepatoma A2 receptor monoclonal antibodies with and without antibody–drug conjugates.

Page 1838

Imaging B cells in an MS model: James and colleagues explore the utility of 64Cu-rituximab, a radiolabeled antibody specifically targeting the human B cell marker CD20, for PET imaging of B cells in a mouse model of multiple sclerosis.

Page 1845

PET and PD-L1: González Trotter and colleagues radiolabel a programmed death ligand 1–binding Affibody molecule with 18F and evaluate its in vitro and in vivo binding affinities, targeting, and specificity in mice.

Page 1852

Somatostatin analog for hybrid imaging: Ghosh and colleagues describe a modular dual-labeling approach with a multimodality chelation scaffold that retains agonistic properties for somatostatin receptor imaging.

Page 1858

New fetal doses for 18F-FDG PET: Zanotti-Fregonara and Stabin offer a revision of fetal dosimetry values calculated from recently published human data in which fetal 18F-FDG uptake was directly observed in vivo.

Page 1865

Metal artifact reduction in PET/CT: van der Vos and colleagues visually analyze and quantitatively assess phantom and patient scans to measure the effect on PET images of iterative metal artifact reduction of CT data.

Page 1867

Sinus/edge-corrected ZTAC: Yang and colleagues evaluate a sinus/edge-corrected zero-echo-time–based attenuation correction approach in brain PET/MR imaging and compare it with a similar uncorrected approach and with CT atlas-based attenuation correction.

Page 1873

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (11)
Journal of Nuclear Medicine
Vol. 58, Issue 11
November 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Nov 2017, 58 (11) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Nov 2017, 58 (11) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18F-FHNP PET
  • Motion-Corrected Imaging of the Aortic Valve with 18F-NaF PET/CT and PET/MRI: A Feasibility Study
  • Test–Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials
  • Nuclear Medicine Training in the United States
  • Diagnostic Performance of the Visual Reading of 123I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia
  • New Fetal Radiation Doses for 18F-FDG Based on Human Data
  • Metabolic Imaging of Infection
  • PET-Guided Evaluation and Optimization of Internalized Antibody–Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor
  • The Evolving Role of Succinate in Tumor Metabolism: An 18F-FDG–Based Study
  • Does Antibiotic Treatment Affect the Diagnostic Accuracy of 18F-FDG PET/CT Studies in Patients with Suspected Infectious Processes?
  • A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases
  • More α Than β for Prostate Cancer?
  • David Versus the Goliaths for the Detection of Bone Metastases
  • Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study
  • Metal Artifact Reduction of CT Scans to Improve PET/CT
  • Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
  • Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
  • Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18F-FDG PET/CT Study
  • Imaging B Cells in a Mouse Model of Multiple Sclerosis Using 64Cu-Rituximab PET
  • Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented
  • A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting
  • 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma
  • Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer
  • 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
  • Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET
  • Evaluation of Sinus/Edge-Corrected Zero-Echo-Time–Based Attenuation Correction in Brain PET/MRI
  • In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
  • Clinical Use and Utility of Amyloid Imaging
  • Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire